Navigation Links
RSB Spine, LLC, Announces FDA Clearance for Its InterPlate(TM) C-PS and L-PS Interbody Spacers
Date:1/28/2010

CLEVELAND, Jan. 28 /PRNewswire/ -- RSB Spine, LLC, today announced that the U.S. Food and Drug Administration has approved the company's 510(k) application to permit the marketing of its InterPlate™ C-PS and L-PS Interbody Spacers.

RSB Spine Chief Executive Officer John A. Redmond said: "We are very excited about this new clearance, since it gives our distributors two additional products to offer customers seeking greater options in Zero-Profile® technologies. Our InterPlate portfolio now provides surgeons with the most unique implant combinations on the market."

"Zero-Profile technologies comprise one of the fastest growing segments in the spinal industry," said Mike O'Neill, president of Paradigm BioDevices. "RSB Spine is the only company with a full-line modular interbody platform offering a complete array of material and mechanical loading options that is also code compliant."

RSB Spine is a privately held medical device company focused on developing innovative spinal implants with a focus on modular fusion products. News releases and other information on the company are available on the Internet at: http://www.rsbspine.com.

Zero-Profile® is a registered Service Mark of Paradigm BioDevices, Inc., Rockland, MA.

SOURCE RSB Spine, LLC

RELATED LINKS
http://www.rsbspine.com

'/>"/>

SOURCE RSB Spine, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
2. RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine
3. Drug Safety Firm BioSoteria Announces Exponential Growth in 2009
4. Sinovac Announces Upsizing and Pricing of Common Share Offering
5. Sudek of Tech Coast Angels Announces Networks Increased Commitment to Entrepreneurship and Innovation Through New Easy-Access Programs
6. Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited
7. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
8. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
9. Firmex Announces Virtual Data Room Enhancements for Large Projects
10. UMass Boston's Venture Development Center Announces New Bio-Science Partner
11. Healthcare Data Solutions Announces New Mobile Application, PrescriberPRO Mobile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of LabKey’s newest software solution, LabKey Biologics . Built in collaboration ... and biotech organizations, LabKey Biologics provides drug research teams tools for biological entity ...
(Date:3/28/2017)... Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or ... data from its phase 1/2 tendon repair study investigating the ... as a treatment for Achilles tendinosis. ... The clinical trial met ... months and showed no serious adverse events related to the ...
(Date:3/27/2017)... ... 27, 2017 , ... IsoPlexis Corporation (IsoPlexis), a venture capital-funded ... more through a single-cell precision engineering platform, today announced it has received an ... the laboratory of Dr. James Heath at the California Institute of Technology, a ...
(Date:3/27/2017)... 27, 2017  The global market for clinical ... to a new report from Kalorama Information.  In ... performed to evaluate disease progression, monitor drug treatment ... reasons.  The healthcare market research firm,s report, ... an overview of the medical laboratory industry and ...
Breaking Biology Technology:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):